Living WELL: A Web-Based Program to Improve Quality of Life in Rural and Urban Ovarian Cancer Survivors
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Ovarian Cancer
- 发起方
- Susan Lutgendorf
- 入组人数
- 326
- 试验地点
- 4
- 主要终点
- Change in HRQOL from baseline (T1) across a 12-month interval post randomization :((T4) Long-term change)
- 状态
- 进行中（未招募）
- 最后更新
- 上个月
概览
简要总结
The purpose of this study is to determine the efficacy of a group-based and web-delivered psychosocial intervention for ovarian cancer survivors (Mindful Living [ML]) compared to a health promotion condition (Healthy Lifestyles [HL]) in increasing health related quality of life (HRQOL) and decreasing perceived stress (primary aim), and decreasing anxiety, depressive mood, and fatigue (secondary aims) across a 12-month period.
详细描述
Living WELL is a randomized clinical trial examining two different programs for helping ovarian cancer survivors cope and improve the quality of their lives following treatment. The programs include techniques and information to enhance both mental and physical well-being. The study is conducted through an internet video conferencing platform and is open to survivors in all parts of the US. The purpose of this study is to examine the effects of various factors such as emotions, stress management and coping techniques, and health information on quality of life, stress levels, depression, fatigue, and distress in ovarian cancer survivors. Participants are randomized into either a Mindful Living group (targeting stress management skills - e.g., relaxation, coping) or a Healthy Lifestyles group (targeting health promotion strategies - e.g, nutrition, sleep, exercise). Participation in this study includes taking part in an introductory online meeting, 10 consecutive weekly online sessions, and follow-up meetings at approximately 4.5 and 9 months following randomization. Each session will be 1.5-2 hours. Participants will complete surveys online prior to beginning the program, within a week after the 10-week program is completed, and at 6 months and 12 months later.
研究者
Susan Lutgendorf
Professor
University of Iowa
入排标准
入选标准
- •Survivors 18 (19 at UNMC since age of Majority is 19 in Nebraska) years or older with a cytological or histological diagnosis of any stage of epithelial ovarian cancer, peritoneal cancer, fallopian tube cancer, or cancer of Mullerian origin consistent with ovarian/fallopian tube/peritoneal origin (not consistent with endometrial cancer). Individuals diagnosed with synchronous ovarian and endometrial cancer primaries may be included if the initial endometrial cancer was stage I.
- •Survivors who have completed primary treatment (surgery and chemotherapy or chemotherapy alone for a new diagnosis ovarian/peritoneal/fallopian tube cancer within the last 5 years). Date of completion of primary treatment is defined as within approximately 60 days after the last chemotherapy infusion. Maintenance therapy infusions do not count in determining date of completion of primary therapy. Women who were not recommended to receive adjuvant chemotherapy (for example, in the case of certain stage IA/IB cancers) are eligible after surgery alone. Women receiving consolidation or maintenance therapy following primary chemotherapy or following treatment for first recurrence are eligible.
- •Survivors must not have had more than one recurrence. Those who have had one recurrence will be eligible if they have completed active therapy for their recurrence.
- •Although most women meeting the above criteria will be in remission, complete clinical remission (normal tumor markers and normal CT scan) is not a requirement for eligibility. Even women with low-level disease after completion of cytotoxic chemotherapy who do not meet the strict definition of remission may have stable disease and may not require additional cytotoxic chemotherapy for a prolonged period of time, particularly if they are on maintenance therapy. If subjects recur during the group they will be allowed to continue to participate, as able, even while taking chemotherapy.
- •Survivors must be fluent in spoken English (6th grade level), which is necessary to participate in the intervention.
- •Survivors must be willing to be randomized and followed for 12 months.
- •Survivors must be able to understand and willing to sign a written informed consent document.
- •Survivors currently involved in the STEPS through Ovarian Cancer program will need to wait until their involvement is completed to participate.
- •Survivors receiving active treatment for another cancer may be eligible when their treatment is completed.
- •Temporary Exclusion:
排除标准
- •Non-epithelial ovarian cancer, ovarian tumors of low malignant potential ("borderline"), cancers originating from other organs. Survivor who have a history of a prior cancer besides their ovarian cancer will be considered eligible as long as they are not in active therapy for said other prior cancer.
- •History of prior inpatient psychiatric treatment for severe mental illness (e.g. psychosis) or current psychosis, history of bipolar disorder or schizophrenia in the last 2 years or current bipolar disorder or schizophrenia, current major depression, history of substance use disorder in the last 2 years or current substance dependence, organic mental disorder (e.g., dementia), or substance use disorder in the last 2 years.
- •Survivors who are younger than 18 or older than 90 years of age
- •Unable to meet study requirements
- •Currently receiving primary chemotherapy.
- •History of depression is not excluded as long as the patient is not currently depressed
- •Survivors who are currently depressed as indicated by a CES-D Score ≥ 24 (can be rescreened once the depressive symptoms resolve).
结局指标
主要结局
Change in HRQOL from baseline (T1) across a 12-month interval post randomization :((T4) Long-term change)
时间窗: 6 months to 12 months post-baseline (T4)
HRQOL will be measured by the Functional Assessment of Cancer Therapy (FACT-O) survey, a health survey designed to assess multiple dimensions of HRQOL. Higher scores indicate better HRQOL Linear mixed models for repeated measures will be used to test for efficacy with p values adjusted using Bonferroni methods to account for the two timepoints.
Change in Perceived Stress from baseline (T1) to T2 (immediate change: post-intervention).
时间窗: Mean change from pre-intervention baseline to T2 (after completion of the 10 week intervention)
Perceived Stress will be measured by the Perceived Stress Scale (PSS) a scale commonly used to assess subjective levels of stress. Higher scores indicate more stress.
Change in HRQOL from baseline (T1) to T2 (immediate change: post-intervention).
时间窗: Mean change from pre-intervention baseline to T2 (after completion of the 10 week intervention)
HRQOL will be measured by the Functional Assessment of Cancer Therapy (FACT-O) survey, a health survey designed to assess multiple dimensions of HRQOL. Higher scores indicate better HRQOL.
Change in Perceived Stress from baseline (T1) across a 12-month interval post randomization: ((T4) Long-term change)
时间窗: 6 months to 12 months post-baseline (T4)
Perceived Stress will be measured by the Perceived Stress Scale (PSS) a scale commonly used to assess subjective levels of stress. Higher scores indicate more stress. Linear mixed models for repeated measures will be used to test for efficacy with p values adjusted using Bonferroni methods to account for the two timepoints.
次要结局
- Change in anxiety from baseline (T1) to T2 (immediate change: post-intervention)(Mean change from pre-intervention baseline to T2 (after completion of the 10 week intervention))
- Change in fatigue from baseline (T1) to T2 (immediate change: post-intervention).(Mean change from pre-intervention baseline to T2 (after completion of the 10 week intervention))
- Change in anxiety from baseline (T1) across a 12-month interval post randomization :((T4) Long-term change)(6 months to 12 months post-baseline (T4))
- Change in fatigue from baseline (T1) across a 12-month interval post randomization :((T4) Long-term change)(6 months to 12 months post-baseline (T4))
- Change in CESD (depressive mood) from baseline (T1) to T2 (immediate change: post-intervention).(Mean change from pre-intervention baseline to T2 (after completion of the 10 week intervention))
- Change in CESD from baseline (T1) across a 12-month interval post randomization :((T4) Long-term change)(6 months to 12 months post-baseline (T4))